Dr. John F. Kuttesch
Claim this profileUniversity of New Mexico Cancer Center
Studies Leukemia
Studies Lymphoblastic Leukemia-Lymphoma
15 reported clinical trials
46 drugs studied
Area of expertise
1Leukemia
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
2Lymphoblastic Leukemia-Lymphoma
BCR-ABL1 fusion positive
ABL-class fusion positive
Philadelphia chromosome positive
Affiliated Hospitals
Clinical Trials John F. Kuttesch is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Dabrafenib + Trametinib After Radiation
for Brain Cancer
This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.
Recruiting1 award Phase 2
More about John F. Kuttesch
Clinical Trial Related4 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments John F. Kuttesch has experience with
- Cyclophosphamide
- Dexamethasone
- Etoposide
- Pegaspargase
- Prednisolone
- Thioguanine
Breakdown of trials John F. Kuttesch has run
Leukemia
Lymphoblastic Leukemia-Lymphoma
Tumors
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John F. Kuttesch specialize in?
John F. Kuttesch focuses on Leukemia and Lymphoblastic Leukemia-Lymphoma. In particular, much of their work with Leukemia has involved BCR-ABL1 fusion positive patients, or patients who are ABL-class fusion positive.
Is John F. Kuttesch currently recruiting for clinical trials?
Yes, John F. Kuttesch is currently recruiting for 3 clinical trials in Albuquerque New Mexico. If you're interested in participating, you should apply.
Are there any treatments that John F. Kuttesch has studied deeply?
Yes, John F. Kuttesch has studied treatments such as Cyclophosphamide, Dexamethasone, Etoposide.
What is the best way to schedule an appointment with John F. Kuttesch?
Apply for one of the trials that John F. Kuttesch is conducting.
What is the office address of John F. Kuttesch?
The office of John F. Kuttesch is located at: University of New Mexico Cancer Center, Albuquerque, New Mexico 87102 United States. This is the address for their practice at the University of New Mexico Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.